An observational study in Insulinoma; Pancreas, sponsored by Sahlgrenska University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 15 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Sahlgrenska University Hospital · Observational
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies.
In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.
Patients (P): Alla patients referred to Sahlgrenska University Hospital for the diagnostic work-up and management of a suspected pancreatic insulinoma.
Intervention (I): EUS-RFA
Control group (C): Patients with insulinoma treated with conventional surgery during the time frame 2018-2025 (historic controls).
Outcome (O):
62 studies on the registry are indexed under Insulinoma; 12 are open to participants now.
Browse Insulinoma studies →Sahlgrenska University Hospital is the lead sponsor of 263 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients referred to Sahlgrenska UH for the diagnosis and treatment of pancreatic insulinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patientens enrolled prospectively from 2025 and onwards subjected to EUS-RFA as treatemtn for pancreatic insulinoma
Procedure: EUS-RFA
All patients subjected to surgery due to insulinoma during 2018-2024 acting as a historic control group
Treatment of insulinoma by EUS-RFA
Clinical efficacy
Symptom-free survival after EUS-RFA (no clinical signs of residual disease, i.e. insulin-producing insulinoma cells)
Time frame: 3-24 months post-EUS
Patient safety
Adverse evnt rate according to Clavien-Dindo at 30 days post-EUS-RFA
Time frame: 30 days post-EUS-RFA
Imaging effect post-EUS-RFA with respect to tumor size
Imaging of the insulinoma by EUS post-EUS-RFA and thereby the assessment of tumor size
Time frame: 3-24 months post-EUS-RFA
Imaging effect post-EUS-RFA with respect to tumor vascularization
Imaging of the insulinoma by EUS post-EUS-RFA and thereby the assessment of remaining tumor vascularization
Time frame: 3-24 months post EUS-RFA
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2028, 45 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sahlgrenska University Hospital →